Dr. Danny Soon, MBBS

Medical Director, D3 (Drug Discovery and Development), Agency for Science, Technology and Research (A*STAR)



Dr. Danny Soon is highly experienced clinical researcher specialising in early clinical phase drug development, having worked for 15 years at the Lilly-NUS Centre for Clinical Pharmacology (LNUS) through several roles. As the Managing Director and Principal Investigator for LNUS, Danny had responsibility and oversight for all clinical Phase 1 studies conducted and operations in the unit. Dr. Soon has been an investigator in over 90 clinical pharmacology studies, including first-in-human studies, biomarker development work, human physiology investigations and pivotal registration PK studies.
Danny has recently joined D3, the drug development unit of the Singapore Agency for Science, Technology and Research (A*STAR), as Medical Director. In this role, he has oversight of the medical aspects of early phase clinical programmes for A*STAR as well as partnered assets. His current portfolio includes oncology and anti-infective medicines.
Danny graduated with MBBS from NUS, and PG Dip in Drug Development Sciences from the University of Surrey.

21st November 2015 (Saturday) 13:50 - 14:15
Session III: Early Clinical Development in Asia
Translational and Early Phase Clinical Research in Singapore